Orca Capital AG's Schedule 13G Filing for Purple Biotech Ltd.

Orca Capital AG, a German entity, has filed a Schedule 13G with the SEC, disclosing its ownership of 605,000 American Depositary Shares (ADS) of Purple Biotech Ltd., representing 9.9% of the outstanding shares. The filing indicates that Orca Capital AG has sole voting and dispositive power over these shares. The ADSs each represent 200 ordinary shares of Purple Biotech Ltd. The filing also notes that Orca Capital AG holds pre-funded and Series B warrants, which are subject to a 4.99% blocker, preventing the entity from exercising the warrants if it would result in ownership exceeding 4.99% of the outstanding ordinary shares. The filing was signed by Thomas Konig, a director of Orca Capital AG, and is effective as of September 9, 2025.